CRISPR 基因组编辑技术的成长：先进疗法走向临床

IF 50.5 1区综合性期刊 Q1 MULTIDISCIPLINARY SCIENCES

Nature Pub Date : 2024-12-17 DOI:10.1038/d41586-024-04102-w

引用次数: 0

摘要

在首款 CRISPR 药物获得批准一年多之后，针对癌症和血液疾病的基因编辑技术日趋成熟。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

CRISPR genome-editing grows up: advanced therapies head for the clinic

Gene-editing technologies for cancer and blood disorders are maturing a little more than a year after the first CRISPR drug was approved.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature 综合性期刊-综合性期刊

CiteScore

90.00

自引率

1.20%

发文量

3652

审稿时长

3 months

期刊介绍： Nature is a prestigious international journal that publishes peer-reviewed research in various scientific and technological fields. The selection of articles is based on criteria such as originality, importance, interdisciplinary relevance, timeliness, accessibility, elegance, and surprising conclusions. In addition to showcasing significant scientific advances, Nature delivers rapid, authoritative, insightful news, and interpretation of current and upcoming trends impacting science, scientists, and the broader public. The journal serves a dual purpose: firstly, to promptly share noteworthy scientific advances and foster discussions among scientists, and secondly, to ensure the swift dissemination of scientific results globally, emphasizing their significance for knowledge, culture, and daily life.